相关实验视频

Updated: Jul 17, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

克拉迪和细胞在儿童中耐火性高风险多系统朗格汉斯细胞囊细胞瘤

Wenqian Wang^1,2,3, Jian Ge^1,2,3, Honghao Ma^1,2,3

¹Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, PR China.

|September 8, 2023

概括

与低剂量 (LDC) 相比,中剂量化疗 (IDC) 治疗耐火的朗格汉斯细胞囊细胞症 (LCH) 改善了无事件生存率. 虽然IDC显示出更高的骨髓抑制,但在不耐药的LCH患者中,这两种疗法的整体存活率相似.

科学领域:

在瘤学瘤学.
儿科血液学儿科血液学
化疗疗方案化疗方案

背景情况:

耐火兰格汉斯细胞囊细胞瘤 (LCH) 缺乏标准化的治疗方案.
多系统和风险器官参与LCH需要有效的治疗策略.

研究的目的:

为了比较低剂量 (LDC) 与中剂量 (IDC) 化疗方案的疗效和安全性,在耐火性多系统LCH.患者中.
评估LDC和IDC治疗之间的应答率,总生存率和无事件生存率.

主要方法:

在2013年1月至2016年12月期间接受治疗的36名耐火多系统LCH患者的回顾性分析.
患者接受了LDC (100毫克/m2 /天×5天;克拉迪布林5毫克/m2 /天×5天) 或IDC (克拉迪布林500毫克/m2 /天×5天;克拉迪布林9毫克/m2 /天×5天).
评估的结果包括总体应答率,总体存活率,无事件存活率和骨髓抑制的发生率.

主要成果:

在四次或八次治疗后,在LDC和IDC组之间没有观察到总体反应率的显著差异.
在IDC组中,5年无事件生存率明显高 (88.9%) 与LDC组相比 (52.9%) (P=0.033).
IDC组的3/4级骨髓抑制 (80%) 比LDC组 (19.2%) (P=0.001) 严重得多,两组的整体存活率相似.

结论:

与低剂量疗法 (LDC) 相比,中剂量化疗疗法 (IDC) 的cytarabine和cladribine显示了耐火多系统LCH无事件生存率的优越性.
尽管骨髓抑制增加,但IDC疗法在延长疾病控制方面具有潜在的益处.
进一步的研究可能会探索策略,以减轻与IDC相关的毒性,同时最大限度地提高其在耐火LCH中的生存益处.

关键词:

克拉德里宾 (cladribine) 是一种药物.赛塔拉宾可以作为一种药物.兰格汉斯细胞的基细胞分裂耐火的耐火的耐火的风险器官风险器官风险器官

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...